SAFETY AND EFFICACY OF THE PD‐L1 INHIBITOR DURVALUMAB WITH R‐CHOP OR R2‐CHOP IN SUBJECTS WITH PREVIOUSLY UNTREATED, HIGH‐RISK DLBCL

Saved in:
Bibliographic Details
Published inHematological oncology Vol. 37; no. S2; pp. 132 - 134
Main Authors Nowakowski, G., Willenbacher, W., Greil, R., Larsen, T.S., Patel, K., Jäger, U., Manges, R.F., Trümper, L., Haioun, C., Everaus, H., Kalakonda, N., Knoble, J., Nully Brown, P., Jørgensen, J.M., Cunningham, D., Domper Rubio, N., Casadebaig, M., Manzke, O., Munoz, J.
Format Journal Article
LanguageEnglish
Published Chichester Wiley Subscription Services, Inc 01.06.2019
Subjects
Immunotherapy
Monoclonal antibodies
PD-L1 protein
Targeted cancer therapy
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ISSN:0278-0232
1099-1069
DOI:10.1002/hon.93_2629